The effects of a prebiotic supplement on exercise induced asthma and markers of airway inflammation

The effects of a prebiotic galactooligosaccharide mixture (B-GOS) on the severity of hyperpnea-induced bronchoconstriction and airway inflammation in adults with asthma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN15022880

Enrollment

Registered

2016-01-06

Start date

2012-12-02

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exercise induced asthma Respiratory Asthma

Interventions

Participants were randomly assigned to receive 5.5 g.day of either galactooligosaccharide B-GOS (Bimuno) or placebo (maltodextrin) (Clasado Ltd, Milton Keynes, UK) for 3 weeks. Participants then foll

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Body mass index (BMI) 20-25 KG.M-2 2. Physically active 3 or more times a week , with each exercise session lasting at least 45 min 3. Non-smoker 4. Non-vegetarian or vegan 5. Asthma sufferers must have own clinically prescribed medication 6. Asthma sufferers must have a GP diagnosis

Exclusion criteria

Exclusion criteria: 1. Predicted forced expiratory volume in 1 second (FEV1) less than 65% 2. Previously diagnosed with COPD, emphysema, chronic bronchitis or similar respiratory illness 3. Previously admitted to hospital for asthma or other breathing difficulties 4. Asthma exacerbation within the last month (Course of steroids, or hospital visit) 5. History of heart failure, pulmonary hypertension, embolism, or other pulmonary heart disease 6. History of recurrent chest infections 7. Smoker 8. Acute infection within the last four weeks 9. Major operation within the past four months 10. Have a history of taking ?-3 PUFA supplements or supplements with antioxidants above recommended intake, or consume more than three fatty fish meals per week 11. Take a daily dose of aspirin or other NSAIDs 12. Currently taking a daily dose of anti-histamine 13. Currently taking long term asthma maintenance medications – corticosteroids, and leukotriene modifiers that you could not refrain from taking for 4 days prior to laboratory session

Design outcomes

Primary

Measure	Time frame
Pulmonary function data (forced expiratory volume in 1 second, forced vital capacity, and peak expiratory flow) at baseline and in response to the eucapnic voluntary hyperpnoea test (in both asthmatic and non-asthmatic groups). Data was collected at day 0 and day 21.	—

Secondary

Measure	Time frame
1. Baseline and post eucapnic voluntary hyperpnoea (EVH) blood sampling for markers of airway inflammation (chemokines CCL11 and CCL17; tumour necrosis factor-alpha (TNF-a); c-reactive protein; and immunoglobulin E) – (collected in both asthmatic and non-asthmatic groups) 2. Fraction of exhaled nitric oxide (collected in asthmatic group only) Serum chemokine and TNF-a levels were measured from blood samples taken at baseline and 15 min, 60 min and 24 h after EVH. Data was collected at day 0 and day 21.	—

Measure

Time frame

1. Baseline and post eucapnic voluntary hyperpnoea (EVH) blood sampling for markers of airway inflammation (chemokines CCL11 and CCL17; tumour necrosis factor-alpha (TNF-a); c-reactive protein; and immunoglobulin E) – (collected in both asthmatic and non-asthmatic groups) 2. Fraction of exhaled nitric oxide (collected in asthmatic group only) Serum chemokine and TNF-a levels were measured from blood samples taken at baseline and 15 min, 60 min and 24 h after EVH. Data was collected at day 0 and day 21.

—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026